Moreover, GBD‐9 overcomes the limitations of BTK inhibitors and GSPT1 degraders in refractory DLBCL and AML treatment, which may have broader clinical application prospects.[145, 146]. This evidence concerns the gene BTK and acute myeloid leukemia.